# A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

> **NCT05245084** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 64 (actual)

## Conditions studied

- Hypertension and Dyslipidemia

## Interventions

- **DRUG:** CKD-386(3)
- **DRUG:** D013, D326, D337

## Key facts

- **NCT ID:** NCT05245084
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-15
- **Primary completion:** 2022-06-06
- **Final completion:** 2022-06-20
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245084, "A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05245084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*